Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
Phase 2
Completed
- Conditions
- Diabetic Macular Edema
- Registration Number
- NCT00040313
- Lead Sponsor
- Eyetech Pharmaceuticals
- Brief Summary
The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections. A total of 176 patients will be enrolled
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with clinically significant DME, VA 20/50-20/320 in the study eye and 20/100 in the fellow eye
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method